Total HIV — Total revenues
Gilead Sciences Total HIV — Total revenues decreased by 13.3% to $5.03B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.7%, from $4.59B to $5.03B. Over 3 years (FY 2022 to FY 2025), Total HIV — Total revenues shows an upward trend with a 6.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market penetration, successful adoption of new drug regimens, or effective pricing strategies within the HIV therapeutic market. A decrease may signal increased generic competition, loss of patent exclusivity, or a shift in patient treatment preferences.
Detailed definition
This metric represents the total gross revenue generated from the sale of pharmaceutical products specifically indicated...
Peer comparison
Comparable to HIV-specific franchise revenues reported by other major biopharmaceutical companies with significant infectious disease portfolios, such as GSK's ViiV Healthcare segment.
gild_segment_total_hiv_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.30B | $4.30B | $4.30B | $4.30B | $4.54B | $4.54B | $4.54B | $4.54B | $4.34B | $4.75B | $5.07B | $5.45B | $4.59B | $5.09B | $5.28B | $5.80B | $5.03B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +5.7% | +0.0% | +0.0% | +0.0% | -4.4% | +9.3% | +6.9% | +7.5% | -15.9% | +10.9% | +3.7% | +9.9% | -13.3% |
| YoY Change | — | — | — | — | +5.7% | +5.7% | +5.7% | +5.7% | -4.4% | +4.4% | +11.6% | +20.0% | +5.6% | +7.2% | +4.0% | +6.4% | +9.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total hiv — total revenues?
- Gilead Sciences (GILD) reported total hiv — total revenues of $5.03B in Q1 2026.
- How has Gilead Sciences's total hiv — total revenues changed year-over-year?
- Gilead Sciences's total hiv — total revenues increased by 9.7% year-over-year, from $4.59B to $5.03B.
- What is the long-term trend for Gilead Sciences's total hiv — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's total hiv — total revenues has grown at a 6.5% compound annual growth rate (CAGR), from $17.19B to $20.75B.
- What does total hiv — total revenues mean?
- The total revenue earned from selling HIV-related pharmaceutical products.